Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Restore CFTR FunctionClosed to enrollment Location: USA, Australia, Europe

    Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor , protocol number NCT02549451 VX15-809-110

    Study 110 is a Phase 3, multicenter study in subjects aged 6 years and older with cystic fibrosis (CF) who are homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation and who participated in Study 109 (NCT02514473) or Study 011B (NCT01897233). Study 110 is designed to evaluate the safety and efficacy of long term treatment of lumacaftor in combination with ivacaftor.

    • Age:

      6-11 years and 12 years and older

    • Mutation(s):

      Homozygous for the F508del-CFTR Mutation

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple US sites & Australia

    Phase 2 study of VX-440 combination drug in people with cystic fibrosis. , protocol number NCT02951182 VX15-440-101

    This study is taking place at multiple care centres accross the US. It will look at the safety and effectiveness of the drug VX-440 in combination with ivacaftor and/or tezacaftor (VX-661)

    • Age:

      18 years and older

    • Mutation(s):

      homozygous or hetrozygous F508del

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      11

    • Length of Participation:

      57

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: USA & Australia

    Phase 3 study of inacaftor in babies who have a CFTR gating mutation , protocol number NCT02725567 VX15-770-124

    This two-part, open label study is taking place at multiple care centers across the US. It will look at the safety and effectiveness of ivacaftor, as well as how the body processes the drug, in babies who have a CFTR gating mutation.

    • Age:

      0 Months to 24 Months

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      8

    • Length of Participation:

      24 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Phase 2a study of Galapagos GLPG2222 in adults with CF , protocol number Galapagos GLPG2222-CL-202

    This study will look at two different dose levels of GLPG2222. The study is placebo-controlled, which means that some participants will receive the study drug and others will receive a placebo. Participants will receive either the study drug or the placebo for 29 days and will be in the study for six to 10 weeks. Researchers will test the drug's safety and effectiveness by monitoring adverse events and other measures.

    • Age:

      18 years and older

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      5

    • Length of Participation:

      10 weeks

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: Australia

    Fungal exposure and fungal-specific IgE in subjects with cystic fibrosis (Australian Cystic Fibrosis Research Trust 2004/052) , protocol number ACTRN12605000156684

    Fungal exposure and fungal-specific IgE in subjects with cystic fibrosis (Australian Cystic Fibrosis Research Trust 2004/052)

    • Age:

      Not Specified

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Anti-InfectiveActive, not recruiting Location: Australia

    A randomised, prospective, double-blind trial of long-term daily versus weekly azithromycin to determine the effect of dose on disease parameters in cystic fibrosis. , protocol number ACTRN12605000162617

    A randomised, prospective, double-blind trial of long-term daily versus weekly azithromycin to determine the effect of dose on disease parameters in cystic fibrosis.

    • Age:

      > 6 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      with 10% of average for last 6 months

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: Australia

    Effect of Positive Expiratory Pressure (PEP) on the duration of the exacerbation-free period in people with cystic fibrosis (CF). , protocol number ACTRN12605000348651

    Effect of Positive Expiratory Pressure (PEP) on the duration of the exacerbation-free period in people with cystic fibrosis (CF).

    • Age:

      Not Specified

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      FEV1 within 15% of their best recorded value as an outpatient for the preceding six months

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Nutritional-GIActive, not recruiting Location: Australia

    Prevalence and predictors of malnutrition and decreased bone density in cystic fibrosis. , protocol number ACTRN12605000426684

    Prevalence and predictors of malnutrition and decreased bone density in cystic fibrosis.

    • Age:

      >18 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Nutritional-GIEnrolling Location: Australia

    Gastric emptying and malnutrition in adults with cystic fibrosis. , protocol number ACTRN12605000427673

    Gastric emptying and malnutrition in adults with cystic fibrosis.

    • Age:

      >18 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: Australia

    Evaluation of CF patient perception of symptom improvement following inhaled antibiotic treatment. , protocol number ACTRN12605000602628

    Diagnosis of CF and chronic PA infection (defined as cultures positive for PA for > 6 months, including most recent culture). Have adequate understanding of English to give informed consent and follow study procedures. Patient must have completed their most recent course of TOBI or aerosolized tobramycin solution or any other aerosolized antibiotic at least 28 days prior to study entry. Parent/guardian of children 6 to 13 years old must agree to complete the CFQ-R and Global Rating of Change Questionnaires. Patient's physician must have decided to prescribe a 28 day course of TOBI for treatment of clinical symptoms (increased cough, increased sputum production/chest congestion, decreased exercise tolerance, or decreased appetite).

    • Age:

      6 years - no stated upper limit

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Displaying results 21-30 (of 142)
     |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|